Treatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations.
aplastic anemia
bone marrow failure
pediatric hematology/oncology
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
19 May 2024
19 May 2024
Historique:
revised:
27
04
2024
received:
11
01
2024
accepted:
30
04
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Severe aplastic anemia (SAA) is a rare potentially fatal hematologic disorder. Although overall outcomes with treatment are excellent, there are variations in management approach, including differences in treatment between adult and pediatric patients. Certain aspects of treatment are under active investigation in clinical trials. Because of the rarity of the disease, some pediatric hematologists may have relatively limited experience with the complex management of SAA. The following recommendations reflect an up-to-date evidence-based approach to the treatment of children with relapsed or refractory SAA.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31075Informations de copyright
© 2024 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48(1):63‐70.
Barone A, Lucarelli A, Onofrillo D, et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato‐Oncology Italian Association (AIEOP). Blood Cells Mol Dis. 2015;55(1):40‐47.
Samarasinghe S, Veys P, Vora A, Wynn R. Paediatric amendment to adult BSH Guidelines for aplastic anaemia. Br J Haematol. 2018;180(2):201‐205.
Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187‐207.
Pierri F, Dufour C. Management of aplastic anemia after failure of frontline immunosuppression. Expert Rev Hematol. 2019;12(10):809‐819.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383‐394.
Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336(7652):1049‐1051.
Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony‐stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995;85(5):1348‐1353.
Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long‐term outcome. JAMA. 2003;289(9):1130‐1135.
Rogers ZR, Nakano TA, Olson TS, et al. Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica. 2019;104(10):1974‐1983.
Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185‐1196.
Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119(23):5391‐5396.
Marsh JC, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Blood. 2013;122(22):3561‐3567.
Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011;17(3):291‐299.
Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem‐cell transplantation from an alternative donor as second‐line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111(3):1054‐1059.
Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998;100(2):393‐400.
Scheinberg P, Townsley D, Dumitriu B, et al. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. Am J Hematol. 2014;89(5):467‐469.
Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r‐ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999;107(2):330‐334.
Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti‐thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133(6):622‐627.
Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment‐naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012;119(2):345‐354.
Brodsky RA, Chen AR, Dorr D, et al. High‐dose cyclophosphamide for severe aplastic anemia: long‐term follow‐up. Blood. 2010;115(11):2136‐2141.
Scheinberg P, Townsley D, Dumitriu B, et al. Moderate‐dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood. 2014;124(18):2820‐2823.
Brodsky RA, Chen AR, Brodsky I, Jones RJ. High‐dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol. 2004;32(5):435‐440.
DeZern AE, Petri M, Drachman DB, et al. High‐dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore). 2011;90(2):89‐98.
Gamper CJ, Takemoto CM, Chen AR, et al. High‐dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. J Pediatr Hematol Oncol. 2016;38(8):627‐635.
Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS. Late complications following treatment for severe aplastic anemia (SAA) with high‐dose cyclophosphamide (Cy): follow‐up of a randomized trial. Blood. 2002;100(13):4668‐4670.
Tisdale JF, Dunn DE, Geller N, et al. High‐dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000;356(9241):1554‐1559.
Audino AN, Blatt J, Carcamo B, et al. High‐dose cyclophosphamide treatment for refractory severe aplastic anemia in children. Pediatr Blood Cancer. 2010;54(2):269‐272.
Risitano AM, Schrezenmeier H. Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: campath (Alemtuzumab). Bone Marrow Transplant. 2013;48(2):186‐190.
Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single‐lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010;148(5):791‐796.
Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11‐19.
Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818‐1825.
Winkler T, Fan X, Cooper J, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019;133(24):2575‐2585.
Shimamura A, Maschan A, Bennett C, et al. Eltrombopag in pediatric patients with previously untreated or refractory/relapsed severe aplastic anemia: the phase ii escalate trial. Blood. 2022;140(1):705‐707. Supplement.
Führer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106(6):2102‐2104.
Scheinberg P, Wu CO, Nunez O, Young NS. Long‐term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr. 2008;153(6):814‐819.e1.
Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99(10):1574‐1581.
Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565‐573.
Kamio T, Ito E, Ohara A, et al. Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group. Haematologica. 2011;96(6):814‐819.
Gupta V, Gordon‐Smith EC, Cook G, et al. A third course of anti‐thymocyte globulin in aplastic anaemia is only beneficial in previous responders. Br J Haematol. 2005;129(1):110‐117.
Clé DV, Atta EH, Dias DS, et al. Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia. Haematologica. 2015;100(9):e345‐e347.
Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100(3):786‐790.
Groarke EM, Patel BA, Gutierrez‐Rodrigues F, et al. Eltrombopag added to immunosuppression for children with treatment‐naive severe aplastic anaemia. Br J Haematol. 2021;192(3):605‐614.
Saracco P, Quarello P, Iori AP, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long‐term observation follow‐up. Br J Haematol. 2008;140(2):197‐205.
Bacigalupo A, Socie G, Hamladji RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015;100(5):696‐702.
D'Souza A, Fretham C, Lee SJ, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26(8):e177‐e182.
Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront‐unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171(4):585‐594.
Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol. 2012;157(3):339‐346.
Maury S, Balere‐Appert ML, Chir Z, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high‐resolution HLA matching between donor and recipient. Haematologica. 2007;92(5):589‐596.
Perez‐Albuerne ED, Eapen M, Klein J, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008;141(2):216‐223.
Petit AF, Kulasekararaj AG, Eikema DJ, et al. Upfront unrelated donor hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: a retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation. Am J Hematol. 2022;97(1):E1‐E3.
Darrigo LG Jr, Colturato V, de Souza MP, et al. Allogeneic bone marrow transplants for pediatric severe aplastic anemia: real‐world data comparing matched related and unrelated donors in a developing country. Retrospective study on behalf of the Pediatric Hematopoietic Stem Cell Transplant Working Group of the Brazilian Bone Marrow Transplantation Society (SBTMO) and the Brazil‐Seattle Consortium (Gedeco). Pediatr Transplant. 2019;23(7):e13552.
Mortensen BK, Jacobsen N, Heilmann C, Sengelov H. Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long‐term overall survival after transplantation with related donors compared to unrelated donors. Bone Marrow Transplant. 2016;51(2):288‐290.
Szpecht D, Gorczynska E, Kalwak K, et al. Matched sibling versus matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia: experience of the polish pediatric group for hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz). 2012;60(3):225‐233.
Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT‐SAA Working Party. Haematologica. 2010;95(6):976‐982.
Pulsipher MA, Lehmann LE, Bertuch AA, et al. A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune‐suppressive therapy for newly diagnosed severe aplastic anemia: a joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium. Pediatr Blood Cancer. 2020;67(10):e28444.
Kekre N, Zhang Y, Zhang MJ, et al. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017;102(7):1291‐1298.
Marsh JC, Pearce RM, Koh MB, et al. Retrospective study of alemtuzumab vs ATG‐based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(1):42‐48.
Marsh RA, Rao MB, Gefen A, et al. Experience with alemtuzumab, fludarabine, and melphalan reduced‐intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant. 2015;21(8):1460‐1470.
Yoshida N, Takahashi Y, Yabe H, et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide. Bone Marrow Transplant. 2020;55(7):1272‐1281.
Peffault de Latour R, Purtill D, Ruggeri A, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2011;17(1):78‐85.
Yoshimi A, Kojima S, Taniguchi S, et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant. 2008;14(9):1057‐1063.
Zhang X, Li Z, Geng W, Song B, Wan C. Effects and predictive factors of immunosuppressive therapy combined with umbilical cord blood infusion in patients with severe aplastic anemia. Yonsei Med J. 2018;59(5):643‐651.
Chan KW, McDonald L, Lim D, Grimley MS, Grayson G, Wall DA. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant. 2008;42(9):589‐595.
Jiang J, Cai Y, Wan L, Yang J, Wang C. Cord blood infusion‐accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia. Int J Hematol. 2020;111(3):360‐368.
Yu Z, Zhou F, Fu Ge L, et al. High‐dose immunosuppressive therapy combined with cord blood infusion and non‐myeloablative peripheral blood stem cell transplantation for patients with severe aplastic anemia. Eur Rev Med Pharmacol Sci. 2013;17(19):2613‐2618.
Li Y, Sheng Z, Niu S, Ge L, Ren C, Zou Y. Rapid and complete reconstitution of autologous haemopoiesis after cord blood infusion in treatment‐naive patients with severe aplastic anemia receiving high‐dose cyclophosphamide/ATG therapy. Eur J Haematol. 2013;90(1):45‐50.
Peffault de Latour R, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018;132(7):750‐754.
Xu LP, Liu KY, Liu DH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T‐cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012;47(12):1507‐1512.
Xu LP, Wang SQ, Wu DP, et al. Haplo‐identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol. 2016;175(2):265‐274.
Xu LP, Zhang XH, Wang FR, et al. Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia. Bone Marrow Transplant. 2017;52(3):381‐387.
Xu LP, Jin S, Wang SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry‐based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25.
Xu ZL, Zhou M, Jia JS, et al. Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. Bone Marrow Transplant. 2019;54(8):1319‐1326.
Wang Z, Zheng X, Yan H, Li D, Wang H. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. Bone Marrow Transplant. 2014;49(12):1481‐1485.
DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA. Alternative donor transplantation with high‐dose post‐transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017;23(3):498‐504.
DeZern AE, Zahurak ML, Symons HJ, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770‐1779.
Arcuri LJ, Nabhan SK, Cunha R, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after haploidentical donor hematopoietic stem cell transplantation with post‐transplantation cyclophosphamide for relapsed/refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2020;26(12):2311‐2317.
Prata PH, Eikema DJ, Afansyev B, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplant. 2020;55(6):1050‐1058.
Esteves I, Bonfim C, Pasquini R, et al. Haploidentical BMT and post‐transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50(5):685‐689.
DeZern AE, Eapen M, Wu J, et al. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single‐arm, phase 2 trial. Lancet Haematol. 2022;9(9):e660‐e669.